What is Oviva?
Founded in 2014 and headquartered in Altendorf, Switzerland, Oviva operates at the intersection of healthcare and technology. The company provides a specialized platform that connects patients suffering from conditions such as obesity, diabetes, and food allergies with professional dietitians. By leveraging a secure smartphone application, Oviva facilitates both face-to-face and remote nutritional counseling, effectively bridging the gap between clinical expertise and accessible digital care. This model has established the company as a leader in the digital health sector, focusing on measurable health outcomes through personalized, data-driven interventions.
How much funding has Oviva raised?
Oviva has raised a total of $313.8M across 5 funding rounds:
Seed
$800K
Series A
$12M
Series B
$21M
Series C
$80M
Series D
$200M
Seed (2016): $800K, investors not publicly disclosed
Series A (2017): $12M led by Albion Capital Group LLP, Walking Ventures, Partech Ventures, F-Prime Capital Partners, and Eight Roads Ventures
Series B (2020): $21M supported by Partech, Earlybird, F-Prime Capital, Albion Capital Group, MTIP, and Eight Roads Ventures
Series C (2021): $80M featuring Earlybird, Mtip, Sofina, F-Prime Capital Partners, Eight Roads, Temasek, and Albion Capital Group
Series D (2026): $200M backed by AP Moller Group, Planet First Partners, EGS Beteiligungen, Sofina, Norrsken Vc, Kinnevik, Temasek, and Lunate
Key Investors in Oviva
AP Moller Group
AP Moller Group is a global conglomerate headquartered in Denmark with operations spanning shipping, logistics, banking, energy, and manufacturing sectors.
Planet First Partners
Planet First Partners is a growth equity platform that invests in and collaborates with disruptive entrepreneurs to scale tech-enabled businesses focused on sustainable practices.
EGS Beteiligungen
EGS Beteiligungen AG is a subsidiary of the Ernst Göhner Stiftung, focusing on long-term investments in Swiss-related companies and growth financing for late-stage technology startups.
What's next for Oviva?
Following this major strategic investment, Oviva is poised to enter a new phase of enterprise-level scaling. The influx of capital will likely be directed toward deepening its market penetration in Europe and potentially exploring new geographic territories. By continuing to integrate advanced digital tools into its nutritional therapy framework, the company aims to solidify its position as a critical component of modern healthcare systems. The focus remains on scaling its B2B and B2C offerings while maintaining the high standard of clinical efficacy that has defined its growth from its early seed stages to its current Series D status.
See full Oviva company page
